Iizuka Yasuhiro, Sakai Hideki, Kobayashi Konomi, Iizuka Kazue, Ito Eri, Mochizuki Nahoko, Asahina Yasuhiro, Watanabe Mamoru
Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital.
Nihon Shokakibyo Gakkai Zasshi. 2014 Aug;111(8):1618-23.
A 64-year-old woman was prescribed lamivudine and adefovir (ADV) for chronic hepatitis B. Although her serum creatinine level was normal (<1.01 mg/dl), she developed bone pain due to Fanconi syndrome and osteomalacia. Therefore, ADV was discontinued and she was switched to entecavir (ETV); however, she developed an ETV-resistant mutant virus and a small dose of ADV was restarted. Her hepatitis B virus (HBV) -DNA levels and renal function were closely monitored. She has had preserved creatinine levels and tubular function, with almost undetectable HBV-DNA levels for more than a year after treatment.
一名64岁女性因慢性乙型肝炎接受拉米夫定和阿德福韦（ADV）治疗。尽管她的血清肌酐水平正常（<1.01 mg/dl），但她因范科尼综合征和骨软化症出现了骨痛。因此，停用了ADV，转而使用恩替卡韦（ETV）；然而，她出现了对ETV耐药的突变病毒，于是重新开始使用小剂量的ADV。密切监测她的乙型肝炎病毒（HBV）-DNA水平和肾功能。治疗后一年多来，她的肌酐水平和肾小管功能保持良好，HBV-DNA水平几乎检测不到。
